학술논문

Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia
Document Type
article
Source
Molecular Psychiatry. 19(9)
Subject
Pharmacology and Pharmaceutical Sciences
Biomedical and Clinical Sciences
Brain Disorders
Serious Mental Illness
Genetics
Schizophrenia
Prevention
Mental Health
Bipolar Disorder
Human Genome
2.1 Biological and endogenous factors
Aetiology
Mental health
Calcium Channels
L-Type
Case-Control Studies
Cell Cycle Proteins
Factor Analysis
Statistical
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Nuclear Proteins
Odds Ratio
Phenotype
Phosphatidylinositol 3-Kinases
Polymorphism
Single Nucleotide
Schizophrenic Psychology
bipolar
clinical symptoms
cross disorder
polygenic
schizophrenia
Schizophrenia Working Group of the Psychiatric Genomics Consortium
Bipolar Disorder Working Group of the Psychiatric Genomics Consortium
Cross-Disorder Working Group of the Psychiatric Genomics Consortium
Biological Sciences
Medical and Health Sciences
Psychology and Cognitive Sciences
Psychiatry
Clinical sciences
Biological psychology
Clinical and health psychology
Language
Abstract
Bipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1 and MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically.